Health Economics›Gastric cancer›Perioperative therapy

Perioperative therapy

Gastric cancer · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
DOX-CapeOx Variant #01	—	R 6 149	21d	—	—	~4	~R 24 595 indirect	—
FLOT Variant #02	—	R 3 835	14d	—	50.0 mo	8	R 30 682 PFS proxy	1
EOX Variant #01	—	R 3 772	21d	—	48.0 mo	9	R 31 213 PFS proxy	1
EOF Variant #01	—	R 3 582	21d	—	48.0 mo	8	R 28 660 PFS proxy	1
ECX Variant #01	—	R 2 632	21d	—	48.0 mo	3	R 7 896 PFS proxy	1
CapeOx Variant #01	—	R 2 620	21d	~6.5 mo	~12.2 mo	~4	~R 10 479 PFS proxy · indirect	16
mFOLFOX6 Variant #02	—	R 2 617	14d	~7.6 mo	~12.2 mo	~6	~R 15 700 PFS proxy · indirect	4
ECF Variant #01	—	R 2 442	21d	—	48.0 mo	9	R 21 982 PFS proxy	2
Cisplatin and Fluorouracil (CF) Variant #01	—	R 1 783	28d	—	55.7 mo	3	R 5 350 PFS proxy	2
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 480	21d	—	55.7 mo	2	R 2 960 PFS proxy	1
SOX Variant #01 Partial	—	R 1 265	21d	~5.6 mo	—	~2	~R 2 530 PFS proxy · indirect	2

11 of 11 regimens shown